There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .
Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer.
CONTEXT Myostatin is a negative regulator of muscle growth . And rogen deprivation ( ADT ) is associated with muscle loss and increased body fat , and currently available therapies have limited efficacy to treat this complication . The antimyostatin peptibody ( AMG 745/Mu-S ) markedly attenuated muscle loss and decreased fat accumulation in orchiectomized mice . OBJECTIVE The objective of the study was to evaluate the safety , pharmacokinetics , and muscle efficacy of AMG 745 in men undergoing ADT for nonmetastatic prostate cancer . METHODS This was a r and omized , blinded , placebo-controlled , multiple-dose , phase 1 study of AMG 745 given for 28 days . The end point of percentage change from baseline in lean body mass ( LBM ) as assessed by dual x-ray absorptiometry was prespecified . RESULTS Rates of adverse events  ( AMG 745 vs placebo ) were the following : diarrhea ( 13 % vs 9 % ) , fatigue ( 13 % vs 4 % ) , contusion ( 10 % vs 0 % ) , and injection site bruising ( 6 % vs 4 % ) . Exposure increased linearly from 0.3 mg/kg to 3 mg/kg . AMG 745 significantly increased LBM in the 3 mg/kg vs the placebo groups on day 29 by 2.2 % ( ±0.8 % SE , P = 0.008 ) ; in exploratory fat mass analysis , a decrease of -2.5 % ( ±1.0 % SE , P = 0.021 ) was observed . Pharmacodynamic changes in muscle and fat were maintained at follow-up , 1 month after day 29 . CONCLUSION Four weekly s.c . doses of AMG 745 were well tolerated and were associated with increased LBM and decreased fat  in the men receiving ADT for nonmetastatic prostate cancer . RESULTS support further investigation of AMG 745 in clinical setting s with muscle loss and atrophy
There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .